Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy DOI Creative Commons
Zheng Gong, Cheng Cheng, Chaonan Sun

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: May 2, 2025

Abstract Extracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability modulate immune responses and deliver therapeutic agents with high specificity minimal toxicity. These nanometer-sized vesicles, which include exosomes (Exos) other subtypes, naturally participate intercellular communication are capable of carrying a diverse range bioactive molecules, including proteins, lipids, RNAs, metabolites. Recent advancements the biogenesis EVs, such strategies modify surface characteristics cargo, significantly expanded potential effective vehicles for targeted therapies. Tailoring contents incorporating immunomodulatory molecules or gene-editing (GETs), has shown outcomes enhancing anti-tumor immunity overcoming immunosuppressive tumor microenvironment (TME). Moreover, optimizing delivery mechanisms, through both passive active targeting strategies, is crucial improving clinical efficacy EV-based This review provides an overview recent developments engineering EVs immunotherapy, focusing on biogenesis, methods content customization, innovations cargo delivery. Additionally, addresses challenges associated translation therapies, issues related scalability, safety, By offering insights into current state field identifying key areas future research, this aims advance application treatment.

Language: Английский

Lipid Coating of Mesoporous Silica Nanoparticles Leads to Efficient Antigen Delivery to Lymph Nodes for Cancer Vaccination DOI
Jia Zhang, Qiang Huang, Honghong Yang

et al.

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

The enrichment of antigens in lymph nodes and the ensuing antigen presentation constitute crucial steps determining efficacy tumor vaccines. However, delivery is restricted by enzyme degradation, immune system clearance, difficulty crossing biological barriers. In this study, mesoporous silica nanoparticles (MSNPs) were prepared for loading further coated with a phospholipid bilayer membrane (named silicasomes) to improve efficiency nodes. Our results showed that silicasomes exhibited superior node compared bare MSNPs following subcutaneous injection. Moreover, their as vaccine was validated B16-OVA model ovalbumin (OVA257-264). Besides, toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A (MPLA), component bacterial lipopolysaccharides, incorporated into on surface an adjuvant. silicasome-OVA257-264 addition MPLA more potent antitumor effect, triggering infiltration specific T cells tumor. These demonstrated coating significantly enhanced enabled synergistic activation adjuvants, highlighting potential effective vehicles cancer immunotherapy.

Language: Английский

Citations

0
Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy DOI Creative Commons
Zheng Gong, Cheng Cheng, Chaonan Sun

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: May 2, 2025

Abstract Extracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability modulate immune responses and deliver therapeutic agents with high specificity minimal toxicity. These nanometer-sized vesicles, which include exosomes (Exos) other subtypes, naturally participate intercellular communication are capable of carrying a diverse range bioactive molecules, including proteins, lipids, RNAs, metabolites. Recent advancements the biogenesis EVs, such strategies modify surface characteristics cargo, significantly expanded potential effective vehicles for targeted therapies. Tailoring contents incorporating immunomodulatory molecules or gene-editing (GETs), has shown outcomes enhancing anti-tumor immunity overcoming immunosuppressive tumor microenvironment (TME). Moreover, optimizing delivery mechanisms, through both passive active targeting strategies, is crucial improving clinical efficacy EV-based This review provides an overview recent developments engineering EVs immunotherapy, focusing on biogenesis, methods content customization, innovations cargo delivery. Additionally, addresses challenges associated translation therapies, issues related scalability, safety, By offering insights into current state field identifying key areas future research, this aims advance application treatment.

Language: Английский

Citations

0